Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-week Phase I/II open-label study of dolutegravir in HIV-1 infected children and adolescents
2010-020988-20Phase 2
- Sponsor
- NIAID Division of AIDS
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dolutegravir in Human immunodeficiency virus infection type 1, sponsored by NIAID Division of AIDS. Primary endpoints: Toxicity through Week 24 and Pharmacokinetic exposure matching adult dose.
02
Drugs
dolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-020988-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020988-20.